A Phase 1, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment.
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2014
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Lexicon Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2013 Results have been reported in a Lexicon Pharmaceuticals media release.
- 01 Oct 2013 Primary endpoint 'Postprandial-glucose-level' has been met according to a Lexicon Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History